Alexandra E. Rojek
Alexandra E. Rojek
Hematology/Oncology Fellow, University of Chicago
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Stress-triggered phase separation is an adaptive, evolutionarily tuned response
JA Riback, CD Katanski, JL Kear-Scott, EV Pilipenko, AE Rojek, ...
Cell 168 (6), 1028-1040. e19, 2017
Reversible, specific, active aggregates of endogenous proteins assemble upon heat stress
EWJ Wallace, JL Kear-Scott, EV Pilipenko, MH Schwartz, PR Laskowski, ...
Cell 162 (6), 1286-1298, 2015
Differences in narrative language in evaluations of medical students by gender and under-represented minority status
AE Rojek, R Khanna, JWL Yim, R Gardner, S Lisker, KE Hauer, C Lucey, ...
Journal of general internal medicine 34 (5), 684-691, 2019
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ...
Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
JK Jasielec, T Kubicki, N Raje, R Vij, D Reece, J Berdeja, BA Derman, ...
Blood, The Journal of the American Society of Hematology 136 (22), 2513-2523, 2020
Biology and treatment paradigms in T cell acute lymphoblastic leukemia in older adolescents and adults
AA Patel, J Thomas, AE Rojek, W Stock
Current Treatment Options in Oncology 21, 1-21, 2020
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
AA Patel, AE Rojek, MW Drazer, H Weiner, LA Godley, MM Le Beau, ...
Blood Advances 5 (20), 4140-4148, 2021
CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions
VM Orellana-Noia, DR Reed, JM Sen, C Barlow, MK Malecek, BS Kahl, ...
Blood 136, 27-28, 2020
Evolution of therapy for limited stage diffuse large B-cell lymphoma
AE Rojek, SM Smith
Blood Cancer Journal 12 (2), 33, 2022
Optimizing synchrotron microCT for high-throughput phenotyping of zebrafish
PJ La Rivière, D Clark, A Rojek, P Vargas, X Xiao, F DeCarlo, ...
Developments in X-Ray Tomography VII 7804, 186-193, 2010
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL
AE Rojek, JP Kline, N Feinberg, DE Appelbaum, Y Pu, BA Derman, ...
Clinical Lymphoma Myeloma and Leukemia 24 (2), 83-93, 2024
Residency Training in the COVID-19 Pandemic—Addressing the Need for Systems-Based Education
AE Rojek, PT Schiller
JAMA Health Forum 3 (9), e223023-e223023, 2022
tRNA expression and tRFs in multiple myeloma: Progression from monoclonal gammopathies to relapsed/refractory disease
AE Rojek, CD Katanski, A Stefka, BA Derman, A Jakubowiak, T Pan
Cancer Research 81 (13_Supplement), 2394-2394, 2021
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis
G Ahmed, A Alsouqi, A Szabo, AE Rojek, PA Riedell, FT Awan, L Samples, ...
Blood 142, 3088, 2023
Residents as Innovators on COVID-19 Respiratory Isolation Units
AE Rojek, PT Schiller
Academic Medicine 97 (7), 946-947, 2022
Impact of pre-treatment whole-body metabolic tumor volume on toxicities and outcomes in patients treated with anti-CD19 CAR T-cell therapy for aggressive large B-cell NHL
AE Rojek, JP Kline, DE Appelbaum, Y Pu, N Feinberg, BA Derman, ...
2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021
Heat shock triggers assembly of tRNA synthetases into an active supercomplex
J Riback, P Laskowski, JL Scott, EWJ Wallace, AE Rojek, MH Schwartz, ...
Biophysical Journal 108 (2), 221a, 2015
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis
A Alsouqi, G Ahmed, J Wang, G Cassanello, A Szabo, AE Rojek, ...
American journal of hematology, 2024
CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement-a multicenter experience.
G Ahmed, A Alsouqi, A Szabo, L Samples, M Shadman, FT Awan, ...
Blood Advances, bloodadvances. 2023012255, 2024
Real World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid Neoplasms
A Kaur, AE Rojek, E Symes, AA Patel, M Nawas, JL Patel, P Sojitra, B Aqil, ...
medRxiv, 2024.03. 11.24303995, 2024
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20